Introduction
The last decade has generated much attention on stem cell research, primarily because of the identification of specific markers and development of methods in mesenchymal stem cells (MSC) isolation, characterization and culturing in vitro. In this article, we first define the clonal oligolineage potential of MSC, emphasizing the rationale for the purification of MSC from other contaminating bone marrow-derived cells. Next, we describe how genetic modification of MSC enriches the bone homing potential of these cells in mouse models. Finally, therapeutic potential of MSC in regenerative medicine and other pathology including tumors is discussed.
What are MSC?
Mesenchymal tissues are remodeled throughout the adult life and this process requires a continuous supply of new cells suggesting the existence of cells, either local or circulating, which have retained their capacity for proliferation and differentiation. MSC are a rare bone marrow stromal cell population that resides primarily in the adult bone marrow and adipose tissue. Nevertheless, there are still some open questions about their true origin, multipotentiality and anatomical localization, as MSC can be isolated from different tissues other than the primary source of bone marrow; such as retina, adipose tissue, liver, inner ear, gastric epithelium, tendons, synovial membrane, amniotic fluid, placenta, umbilical cord, hair follicle and teeth. [1] [2] [3] MSC are considered nonhematopoietic multipotent stem-like cells that have selfrenewing potential, capable of differentiating into both mesenchymal and non-mesenchymal lineages. 4, 5 In much of the literature, the adherent fibroblastic cells from the bone marrow are termed MSC or mesenchymal progenitor cells; however, this heterogeneous population is recognized, among leading investigators, to be too 'crude' to be considered all MSC and the thinking about these bone marrow-derived cells will likely be redefined over the coming years.
Isolation, expansion and phenotyping of MSC
The principal source of MSC is the bone marrow. MSC constitute a small percentage (0.01-0.001% of mononuclear cells isolated on ficoll/percoll density gradient) of the total number of bone marrow-populating cells. The number of MSC isolated from bone marrow may vary in terms of the yield and quality, even when the cells are obtained from identical animals. A typical protocol to obtain MSC from mouse bone marrow is described elsewhere. 4 The addition of FGF2 in MSC cultures helps to maintain the cells in pluripotent and undifferentiated state. Normally, residual macrophages from the MSC culture are removed using anti-mouse CD11b beads. The adherent stromal cells are split prior to attaining confluence to avoid possible onset of differentiation. The cells are routinely prepared and used for in vitro and in vivo studies as low passage cultures.
Culture 
Differentiation potential of MSC
In addition to the identification of MSC, based on their morphological or phenotypical characteristics, their multilineage potential can be determined by differentiating them in vitro to different cell types under appropriate culture conditions. To promote adipogenic differentiation, MSC cultures are incubated with dexamethasone, insulin, isobutyl methyl xanthine and indomethacin. After 3-4 weeks of incubation in adipogenic lineage differentiation medium, lipid-rich vacuoles within the cells can be stained with oil red O stain. 9 The well-established method for osteoblast lineage differentiation is in vitro incubation of monolayer MSC with ascorbic acid, dexamethasone and b-glycerophosphate for 3-4 weeks. Calcium accumulation in the MSC nodules can be positively stained with von Kossa stain. 9 For the chondrogenic differentiation, MSC are centrifuged after trypsinization to form a pellet micromass and cultured in the presence of TGF-b, dexamethasone, sodium pyruvate, ascorbic acid-2-phosphate, proline and insulin-transferrin selenium. After 4 weeks of incubation in the medium, a strong staining with toluidine blue indicates an abundance of glycosaminoglycans within the extracellular matrix. 9 Vascular smooth muscle differentiation of MSC may be obtained in long-term culture medium with horse serum, fetal bovine serum, L-glutamine, L-serine, L-asparagine, sodium pyruvate, sodium bicarbonate, hydrocortisone and antibiotics. 9 Mesenchymal stem cells can also be differentiated into neurons, astrocytes, tenocytes, skeletal myocytes and cells of visceral mesoderm (endothelial cells).
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Bone targeting of culture-expanded murine MSC by ectopic expression of murine a4 integrin Despite the potential of MSC in tissue regeneration, a major limitation remains in the delivery of ex vivo modified MSC to target tissues upon autologous transfer. In our recent study, we have shown that ectopic expression of a4 integrin on mouse MSC resulted in significant increase in bone specific retention of transplanted mouse MSC. 15 Applying the same strategy with some modifications, other cell-specific ligands may be expressed on MSC for the multiple tissue targeting.
Potential clinical application of MSC
Multilineage potential of MSC offers a promising source for stem cell therapy and gene therapy applications. However, compared to details from in vitro studies, less information is available for the behavior of transplanted MSC in vitro. Several groups have demonstrated the use of bone marrow cells for the repair of infarcted myocardium. 16, 17 Reports indicate that injection of murine MSC into healthy adult myocardium resulted in neo-angiogenesis near the injection site within a week after transplantation. [18] [19] [20] Donor cells could be identified within these vessels, and it was shown that transplanted cells had differentiated into cardiomyocytes, endothelial cells and pericytes or smooth muscle cells, demonstrating that culture expanded MSC have the ability to engraft into healthy as well as injured tissue and differentiate into different cell types. 21, 22 In a rat spinal cord-injury model, MSC formed bundles bridging the epicenter of the injury and guided regeneration through the spinal cord lesion, prompting recovery. 23 This implies that the therapeutic benefit of MSC can be achieved by local production of growth factors in the injured spinal cord. One report of murine MSC injection into lateral ventricle in the brain of three-day-old mice had shown MSC migration throughout the forebrain and cerebellum, suggesting the notion that MSC mimic the behavior of neural progenitor cells in this setting. 24 Other studies have shown that MSC transplantation into fetal or neonatal animals have resulted in the engraftment to different tissues without provoking an immune response. 25, 26 Even though most of the MSC get trapped in the lungs after intravenous injection, evidence shows that MSC are capable of homing to the injured tissue after intravenous injection. Cultured rat and human MSC have been shown to migrate into the sites of brain injury after cerebral ischemia when transplanted intravenously in rats. 27, 28 MSC have also been used to treat lung injury in mice upon intravenous injection. MSC have been shown to home to lung in response to injury, adopt an epithelium-like phenotype and reduce inflammation and collagen deposition in the lung tissue of mice in a pulmonary fibrosis model of mice. 29 MSC, transplanted in children with osteogenesis imperfecta, have been shown to migrate to bone and give rise to osteoblasts with an improvement in bone structure and function. 30 Recent studies have investigated the use of MSC for gene therapy, including transplantation of MSC Therapeutic potential of MSC S Kumar et al transiently expressing vascular endothelial growth factor for the improvement of heart function in myocardial rat infarction models. 31 MSC expressing BMP2 to promote bone formation and MSC as a vehicle for interferon-b delivery into tumors in mice have also been reported. 32 Several evidences support that MSC can home to injured or inflamed tissues migrating across endothelial cell layers. [33] [34] [35] However, the mechanism by which MSC home to the tissue and migrate across endothelium is not yet fully understood.
MSC in cancer therapy
The microenvironment of a solid tumor is similar to the milieu of injured or stressed tissue. 36 Most evidence in the recent literature suggested migration of MSC along with other bone marrow-derived cells to the sites of primary tumor and pre-metastatic niche, eventually forming a vital component of the tumor stroma. 37, 38 Several studies with transplantable tumors in mice have shown homing of MSC to many different cancers. [39] [40] [41] [42] As better understanding of the biology of MSC and cancer cell interaction is growing, many studies have successfully employed bone marrow-derived MSC as therapeutic agents to treat a wide range of cancers.
Lung metastasis
Lung remains one of the most popular destinations for cancer cell metastasis and patients with lung metastasis have less than 5 years median survival. The payload of tumor homing MSC in cancer therapy was determined further in a study involving a conditionally replicating adenovirus vectors. 43 Improved transduction of adenoviral vectors to MSC has been shown using modification to include the RGD (Arg-Gly-Asp) motif on the penton fiber. Adopting this strategy, Kanehira et al. 44 transduced NK4, an antagonist of hepatocyte growth factor and significantly prolonged the survival of mice bearing colon-26 cell line xenograft in lungs by inhibiting angiogenesis and lymphangiogenesis and inducing apoptosis of tumor cells. Antitumor activity of retrovirus vector transduced MSC, producing IL-12, has been tested in a mouse melanoma model. 45 MSC-IL-12 but not control MSC strongly reduced the formation of lung metastases of B16F10 melanoma cells in this study.
Bone metastasis
Prostate, breast and lung cancers are the most common malignancies in adults and are the most common tumors that metastasize to bone. Moreover, bone metastasis affects more than 60% of advanced stage breast and prostate cancer patients. Carcinomas of the lung, kidney and thyroid, and melanoma are other common tumors that metastasize to bone. Majority of the tumors that relocate in bone produce predominantly osteolytic lesions with the exception of prostate cancer that produces an osteoblastic phenotype. Osteolysis is a major cause of morbidity and mortality in patients with advanced disease. The potential of MSC, modified to express osteogenic factors, in bone regeneration can be adapted to treat bone damage in cancer patients with osteolytic lesions. Rabin et al. 46 used MSC, transduced by a lentivirus vector to express human OPG (osteoprotegerin), for the treatment of osteolysis in KMS-12-BM xenogenic model of myeloma bone disease. The primary mechanism for bone destruction in bone metastasis is due to osteoclastic bone resorption. The binding of RANKL to RANK on pre-osteoclasts is responsible for the maturation and activity. Increased expression of RANKL has been observed in osteolytic malignancies and inhibition osteoclastogenesis has been considered an intervention strategy. OPG is a soluble decoy receptor for RANKL and prevents binding of RANKL to RANK, leading to inhibition of osteoclast activity. OPG, therefore, promises tremendous hope for potential clinical use in the management of osteolytic bone disease. Notably, systemic expression of OPG, using MSC, has been shown to significantly reduce osteoclast activity and trabecular bone loss in the vertebrae and tibiae of diseased animals. 46 Similarly, bone targeted expression of factors preventing osteoblast production such as noggin can be adapted to minimize osteoblast bone pathology in prostate cancer.
Graft-versus-host disease
Allogenic bone marrow transplantation is a common therapeutic procedure in leukemia. But often, T cells present in the donor marrow elicit immune response against the recipient, thereby rejecting the transplanted cells. Immunosuppression by corticosteroids results in reduced graft-versus-host disease but also increases the chance of acquiring infections. 47 Ex vivo expanded MSC have been reported to suppress the ongoing immune responses and can engraft successfully in a wide range of immunological barriers. 48 In a recently completed study, expanded MSC from an HLA-identical sibling were coinfused with unmanipulated bone marrow or peripheral blood cells in 40 patients with hematological malignancies and were shown to result in hematopoietic reconstitution. 49 But the study failed to show significant reduction in acute graft-versus-host disease and escalation of the number of infused MSC is a possible solution.
Prognostic and diagnostic uses of MSC
Completion of the human genome project had identified all the human genes, and allowed the identification of dysfunctional mutations. Presently, the human healthcare is severely limited by the inability of accurate phenotypic description of each patient and how these attributes change with age and disease states. Unique genotypes of the human population would predict different drug and bioactive factor reactivities of each patient. With the ability to isolate, expand and study MSC in vitro, the MSC of individual patients could be tested for their sensitivity to various drugs, cytokines, growth factors and inductive agents. Optimized treatment plans could then be created, which efficiently and precisely integrate with the expected biological response of the host. Both prognostic and diagnostic assays can be established to predict and treat a specific patient by understanding how MSC turnover activity is controlled and how it changes with the age of the patient.
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Conclusions
Gene modified MSC have shown additive or augmented therapeutic effects in several preclinical models of human diseases. The basic and pre-clinical studies using MSC provides us with the potential of these cells amidst challenges emerging at the crossroads of stem cell tissue engineering, gene therapy and cancer biology. Despite the preliminary success in various animal models and great amount of available data, many fundamental questions still need to be resolved. Although several cell surface markers can be used to recognize MSC, no unique marker for these cells is still identified. Thus, it is challenging to estimate the in vitro culture homogeneity and to identify MSC niches in vivo. Molecular pathways regulating the lineage commitment/development still need to be investigated, in spite of the existing knowledge on mesenchymal lineage-inducing agents. Finding suitable animal models for developing human therapy strategies is also a common problem. For example, bone morphogenetic protein-2 in low doses induce mouse MSC into the osteogenic lineage. At the same time, very high doses are necessary to have the same effect with human MSC. 50 Despite greater enthusiasm on the promise of MSC in regenerative medicine and cell therapy, more evidence are needed in support of mesenchymal stem cell therapy such as: how many cells to inject for a particular application (cell dosing)? How to inject the cells (cell delivery)? Where to inject the cells in localized therapy for therapeutic effect? When to inject the cells? Also, questions regarding the safety, efficacy and long-term fate of the transplanted MSC in animal models need to be answered in greater detail for effective utilization of MSC for human diseases.
